bluebird bio is not the first company to give up on commercializing its product in the fragmented, single payer and price-sensitive markets of Europe. Underestimating the challenges of the European market and failing to commercialize approved products should be recognized as a corporate weakness.
Gene therapy company bluebird’s recent European exit after failing to agree a price in Germany for its one-and-done treatment Zynteglo...




